share_log

復星醫藥：海外監管公告 - 關於為控股子公司提供擔保的進展公告

FOSUN PHARMA: Overseas Regulatory Notice - Announcement on the Progress of Providing Guarantees to Subsidiaries

HKEX ·  Nov 8 18:45

Summary by Futu AI

上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年11月8日宣布，旗下控股子公司為相關控股子公司的融資項下債務提供擔保。具體包括復星診斷科技（上海）有限公司（「復星診斷」）為其控股子公司復星診斷科技（長沙）有限公司（「復星診斷長沙」）向長沙銀行申請的不超過人民幣15,000萬元的融資提供擔保，以及其他三項擔保案例。截至2024年11月7日，包括本次擔保在內，復星醫藥集團實際對外擔保金額折合人民幣約3,075,095萬元，約占2023年12月31日集團經審計的歸屬於上市公司股東净资产的67.31%。本次擔保是在2023年度股東大會批准的担保额度内進行，並且董事會認為該擔保事項是基於集團經營需要而發生，且風險相對可控。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年11月8日宣布，旗下控股子公司為相關控股子公司的融資項下債務提供擔保。具體包括復星診斷科技（上海）有限公司（「復星診斷」）為其控股子公司復星診斷科技（長沙）有限公司（「復星診斷長沙」）向長沙銀行申請的不超過人民幣15,000萬元的融資提供擔保，以及其他三項擔保案例。截至2024年11月7日，包括本次擔保在內，復星醫藥集團實際對外擔保金額折合人民幣約3,075,095萬元，約占2023年12月31日集團經審計的歸屬於上市公司股東净资产的67.31%。本次擔保是在2023年度股東大會批准的担保额度内進行，並且董事會認為該擔保事項是基於集團經營需要而發生，且風險相對可控。
Shanghai Fosun Pharma Group Co., Ltd. (referred to as "Fosun Pharma") announced on November 8, 2024 that its holding subsidiary provided guarantees for the financing debts of related holding subsidiaries. Specifically, Fosun Diagnostics Technology (Shanghai) Co., Ltd. ("Fosun Diagnostics") provided guarantees for the financing not exceeding RMB 150 million applied by its holding subsidiary Fosun Diagnostics Technology (Changsha) Co., Ltd. ("Fosun Diagnostics Changsha") to Bank of Changsha, as well as three other guarantee cases. As of November 7, 2024, including this guarantee, Fosun Pharma Group actually guaranteed an amount equivalent to approximately RMB 30,750.95 million, accounting for approximately 67.31% of the attributable net assets of the listed company shareholders as of December 31, 2023 audited by the board of directors. This guarantee was carried out within the approved guarantee amount at the 2023 shareholder meeting, and the board of directors considers the guarantee to be based on the operation needs of the group, with relatively controllable risks.
Shanghai Fosun Pharma Group Co., Ltd. (referred to as "Fosun Pharma") announced on November 8, 2024 that its holding subsidiary provided guarantees for the financing debts of related holding subsidiaries. Specifically, Fosun Diagnostics Technology (Shanghai) Co., Ltd. ("Fosun Diagnostics") provided guarantees for the financing not exceeding RMB 150 million applied by its holding subsidiary Fosun Diagnostics Technology (Changsha) Co., Ltd. ("Fosun Diagnostics Changsha") to Bank of Changsha, as well as three other guarantee cases. As of November 7, 2024, including this guarantee, Fosun Pharma Group actually guaranteed an amount equivalent to approximately RMB 30,750.95 million, accounting for approximately 67.31% of the attributable net assets of the listed company shareholders as of December 31, 2023 audited by the board of directors. This guarantee was carried out within the approved guarantee amount at the 2023 shareholder meeting, and the board of directors considers the guarantee to be based on the operation needs of the group, with relatively controllable risks.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    SINOLIFE UTD
    03332
    -- 0.650
    REGENT PACIFIC
    00575
    -- 0.375
    LEE'S PHARM
    00950
    -- 1.340
    HEC CJ PHARM
    01558
    -- 10.180
    TIANDA PHARMA
    00455
    -- 0.196

    Unlock the Full List